Literature DB >> 17551350

Magnitude and impact of comorbidity of mental disorders from epidemiologic surveys.

Kathleen R Merikangas1, Amanda Kalaydjian.   

Abstract

PURPOSE OF REVIEW: To consider comorbidity across multiple classes of disorders in data derived from recent large-scale community surveys. RECENT
FINDINGS: There has been substantial recent progress in our understanding of patterns and implications of comorbidity of mental disorders. There is now converging evidence on the magnitude and specific patterns of comorbidity in international studies worldwide. There is increasing recognition of comorbidity of mental and physical disorders. Comorbidity of mental disorders and substance abuse has now been recognized universally, and the results of treatment and prevention studies incorporating comorbidity are now beginning to emerge.
SUMMARY: Comorbidity has been shown to be an index of more severe course and outcome of mental disorders. Systematic inclusion of comorbidity into clinical evaluation and treatment will enhance the effectiveness of intervention with these conditions. Prevention of the development of secondary conditions as a consequence of primary disorders should reduce the impact of these conditions on both the individual and society.

Entities:  

Mesh:

Year:  2007        PMID: 17551350     DOI: 10.1097/YCO.0b013e3281c61dc5

Source DB:  PubMed          Journal:  Curr Opin Psychiatry        ISSN: 0951-7367            Impact factor:   4.741


  34 in total

Review 1.  Cardiovascular morbidity and mortality in bipolar disorder.

Authors:  Miriam Weiner; Lois Warren; Jess G Fiedorowicz
Journal:  Ann Clin Psychiatry       Date:  2011-02       Impact factor: 1.567

2.  The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample.

Authors:  Jess G Fiedorowicz; Jianping He; Kathleen R Merikangas
Journal:  J Psychosom Res       Date:  2010-09-18       Impact factor: 3.006

Review 3.  Treatment of substance abusing patients with comorbid psychiatric disorders.

Authors:  Thomas M Kelly; Dennis C Daley; Antoine B Douaihy
Journal:  Addict Behav       Date:  2011-09-14       Impact factor: 3.913

4.  Harnessing the power of yeast to elucidate the role of sphingolipids in metabolic and signaling processes pertinent to psychiatric disorders.

Authors:  Shyamalagauri Jadhav; Miriam L Greenberg
Journal:  Clin Lipidol       Date:  2014-11-01

5.  Leisure as a context for active living, recovery, health and life quality for persons with mental illness in a global context.

Authors:  Yoshitaka Iwasaki; Catherine P Coyle; John W Shank
Journal:  Health Promot Int       Date:  2010-06-12       Impact factor: 2.483

6.  Integrating structural and epidemiological research to inform the classification of psychopathology.

Authors:  Ayelet Meron Ruscio
Journal:  Int J Methods Psychiatr Res       Date:  2009-12       Impact factor: 4.035

7.  Association of respondent psychiatric comorbidity with family history of comorbidity: Results from the National Epidemiologic Survey on Alcohol and Related Conditions-III.

Authors:  Jeesun Jung; Risë B Goldstein; Bridget F Grant
Journal:  Compr Psychiatry       Date:  2016-08-08       Impact factor: 3.735

8.  Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report.

Authors:  Bernhard T Baune; Harris Eyre
Journal:  J Med Case Rep       Date:  2010-01-12

9.  Educational inequalities in the co-occurrence of mental health and substance use problems, and its adult socio-economic consequences: a longitudinal study of young adults in a community sample.

Authors:  J O Lee; T I Herrenkohl; R Kosterman; C M Small; J D Hawkins
Journal:  Public Health       Date:  2013-07-17       Impact factor: 2.427

10.  Long-term outcome of in-patients with substance use disorders: A study from North India.

Authors:  Shubh M Singh; Surendra K Mattoo; Alakananda Dutt; Kaustav Chakrabarti; Naresh Nebhinani; Suresh Kumar; Debasish Basu
Journal:  Indian J Psychiatry       Date:  2008-10       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.